Agenus Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus or view top-rated stocks.

Wall Street analysts have given Agenus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agenus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Agenus.

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported ($0.27) EPS for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.04. The biotechnology company had revenue of $11.72 million for the quarter, compared to the consensus estimate of $21.81 million.
View Agenus' earnings history.

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGEN stock has increased by 93.4% and is now trading at $5.26.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12 month target prices for Agenus' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Agenus' stock price to reach $8.00 in the next year. This suggests a possible upside of 52.1% from the stock's current price.
View analysts' price targets for Agenus or view top-rated stocks among Wall Street analysts.

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of AGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.41%), RTW Investments LP (6.19%), Oracle Investment Management Inc. (4.21%), Cormorant Asset Management LP (3.48%), Millennium Management LLC (1.84%) and Geode Capital Management LLC (1.26%).
View institutional ownership trends for Agenus.

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Morgan Stanley, Millennium Management LLC, Ikarian Capital LLC, BlackRock Inc., Credit Suisse AG, Verition Fund Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Agenus or view top insider-selling stocks.

AGEN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RTW Investments LP, Citigroup Inc., Cormorant Asset Management LP, Rafferty Asset Management LLC, Nuveen Asset Management LLC, Geode Capital Management LLC, and UBS Group AG.
View insider buying and selling activity for Agenus or or view top insider-buying stocks.

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGEN stock can currently be purchased for approximately $5.26.

Agenus has a market capitalization of $1.17 billion and generates $88.17 million in revenue each year. The biotechnology company earns $-180,910,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

Agenus employs 359 workers across the globe.

The official website for Agenus is agenusbio.com.

Agenus is headquartered at 3 FORBES ROAD, LEXINGTON MA, 02421.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400 or via email at [email protected]